Received Oct 31, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PPV | PNEUMO (PNEUMOVAX) | MERCK & CO. INC. | UNK | — | OT |
she received PNEUMOVAX 23 on 09/18/2025, then got pneumonia a month later.; This spontaneous report was received from a consumer reporting on themselves and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 18-Sep-2025, the patient was vaccinated with Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) solution for injection (exact dose, dose number, route of administration, anatomical location, lot # and expiration date were not reported), for prophylaxis. In approximately October 2025 (reported as "a month later"), the patient experienced pneumonia. The outcome of the event was not reported. The action taken with the suspect vaccine regarding the event was not reported but assessed as not applicable. The causal relationship between pneumonia and Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23) was not provided. Upon internal review, the event of pneumonia was determined to be medically significant.